Superficial transitional cell carcinoma of the ureteral orifice: Higher risk of developing subsequent upper urinary tract tumors

AIM: Reports specifically addressing transitional cell carcinoma (TCC) of the ureteral orifice are scarce. This paper presents our experiences of such tumors, including the characteristics of the disease and the incidence of subsequent upper urinary tract recurrence. METHODS: This study included 572 new cases of TCC of the urinary bladder diagnosed in our institute during a period of 5 years. Thirty-one (5.4%) patients had superficial tumors involving ureteral orifices. All 31 patients underwent transurethral resection of the bladder tumors, including the involved ureteral orifices. After the surgery, patients received regular follow up with cystourethroscopy, urine cytology and periodic intravenous pyelography (IVP). Ureterorenoscopy was performed in cases of suspicious IVP or urine cytology findings. RESULTS: Thirty-one patients with superficial tumors involving the ureteral orifice were followed up for 5-8 years or until death. The pathological stage was Ta in 16 cases and T1 in 15 cases. Bladder tumor recurrence was noted in three (18.8%) of the pTa patients and in seven (46.7%) of the pT1 patients. Subsequent upper urinary tract tumors developed in four (12.9%) patients between 33 and 67 months (mean: 33.5) after the first transurethral resection. All four cases of upper tract recurrence had pT1 primary bladder tumor, which recurred for 1-3 times (mean 1.8) before upper tract recurrence. None of these patients had ureteral stenting after bladder tumor resection. Three of four patients with upper tract recurrence had single lower ureteral tumor, while the remaining one patient had multiple tumors. Patients with subsequent upper urinary tract tumors underwent nephroureterectomy and bladder cuff excision. One died of the disease; the other three cases were free of the disease after the therapy. CONCLUSIONS: Patients with primary superficial bladder transitional cell carcinoma involving the ureteral orifice have a higher risk of developing subsequent upper urinary tract tumors, particularly for pT1 primary bladder tumors. Frequent and close follow up is recommended.     

A clinical study of associated bladder cancer in patients with renal pelvic and ureteral cancer

We reviewed 76 cases of renal pelvic and ureteral cancer, admitted to our hospital between January, 1975 and December, 1988, with special reference to the occurrence of bladder cancer. Bladder cancer was associated with an upper urinary tract neoplasm in 35 of the 76 cases (46.1%), 7 with a preceding bladder cancer, 17 with a coexistent one and 11 with a subsequent one. In case of renal pelvic and upper ureteral cancer the incidence of coexistent or subsequent tumors of the bladder was 28.7% (16 of 56 patients). However, in the cases of lower ureteral cancer the incidence of these tumors was 82.4% (14 of 17 patients). This incidence was significantly higher than that in renal pelvic and upper ureteral cancer. The subsequent bladder cancer was observed in 19 patients including 8 patients who had a recurrence of the bladder cancer after the treatment for a preceding and coexistent bladder cancer. The cancer in most cases occurred within 2 years after the treatment of the upper urinary tract neoplasm. Of 19 patients who had subsequent bladder cancer 11 had primary sites in the renal pelvis and upper ureter. Another 8 patient had primary sites in the lower ureter. Four of the 8 subsequent bladder cancers in patients with lower ureteral cancer occurred just on and around the affected ureteral orifice. All these 4 tumors were high grade and high stage tumors. On the other hand, another 15 patients developed subsequent bladder cancer in a place other than the affected ureteral orifice. Of these 15 patients, 13 cases showed a low grade and low stage tumor.(ABSTRACT TRUNCATED AT 250 WORDS)     

肾移植术后并发双侧自体肾盂和输尿管移行细胞癌16例

目的 总结肾移植术后发生双侧自体肾盂、输尿管移行细胞癌的诊治经验.方法 回顾性分析16例肾移植术后发生双侧自体肾盂、输尿管移行细胞癌患者的资料.首次发现上尿路肿瘤的时间为移植后(56.2±33.0)个月.2例同时发现双侧上尿路肿瘤,其余14例双侧上尿路肿瘤先后发现的时间间隔为(8.6±6.7)个月.临床症状和检查阳性结果以血尿和自体肾积水为主.均行自体上尿路根治性切除术,术后行膀胱灌注化疗.结果 16例手术均成功.32次自体肾、输尿管的病理检查结果均为移行细胞癌,包括单纯肾盂肿瘤4次,单纯输尿管肿瘤9次,合并肾盂、输尿管肿瘤19次.23次肾盂肿瘤的分级为1级8例,2级11例,3级4例;28次输尿管肿瘤的分级为1级6例,2级10例,3级12例.术后随访(26.8±25.1)个月,1例出现肺部转移后死亡;1例发生腰背部软组织转移性移行细胞癌,局部切除;其他患者未发现肿瘤复发及转移.结论 肾移植后自体上尿路移行细胞癌的常见表现为血尿合并自体肾积水,该肿瘤侵袭性较强,对于膀胱及一侧自体上尿路同时存在移行细胞癌者,应行对侧自体肾上尿路预防性切除术.

Abstract：

Objective To investigate the clinical features of bilateral native pelvic and ureteral transitional cell carcinoma (TCC) in renal transplant patients. Methods A retrospective analysis was carried out on 16 patients with bilateral native pelvic and ureteral TCC after kidney transplantation.The mean time between transplantation and diagnosis of upper urinary TCC was 56. 2 ± 33. 0 months.Two patients were suffered from bilateral upper urinary TCC at the same time. The mean interval between 2 upper urinary tract operations of the remaining 14 cases was 8. 6 ± 6. 7 months. Hematuria and hydronephrosis of native kidneys were the main symptoms and targets in checkup. Intravesical chemotherapy was postoperatively given. Results All operations were performed successfully. All specimens obtained from the operations were pathologically diagnosed as TCC. The TCC location involved pure native pelvis (n = 4), pure native ureter (n = 9), and pelvis combined with ureter (n = 19). Pelvic TCC pathological grades included grade 1 in 8 cases, grade 2 in 11 cases, and grade 3 in 4 cases; Ureteral TCC grades included grade 1 in 6 cases, grade 2 in 10 cases, and grade 3 in 12 cases.Patients were followed up for 26. 8 ± 25. 1 months. One patient died of lung metastasis. (One case of lumbar soft tissue transfer was given local excision. The remaining patients had no recurrence and metastasis. Conclusion Renal transplant patients with hematuria and native renal hydronephrosis should be highly vigilant of the occurrence of upper urinary tract TCC. TCC after renal transplantation is invasive. Prophylactic contralateral nephroureterectomy should be performed on the recipients having TCC at the bladder and one side of native upper urinary tract.     

泌尿系子宫内膜异位症临床诊治特点分析

目的 探讨泌尿系子宫内膜异位症的临床诊治特点.方法 女性泌尿系子宫内膜异位症患者10例.平均年龄39(28～49)岁.病史6个月～3年.膀胱子宫内膜异位症4例,临床表现为月经期尿路刺激症、下腹部坠痛不适感,其中伴肉眼血尿1例.B超、CT检查提示膀胱占位病变直径2.0～3.5 cm.输尿管子宫内膜异位症6例,左侧4例,右侧2例.临床表现为腰腹部不适4例,间断无痛性肉眼血尿1例,查体B超偶然发现肾积水1例.B超检查肾盂分离2.0～4.5 cm,输尿管中上段扩张1.0～2.0 cm,其中1例输尿管下端占位伴肾重度积水;CT检查输尿管下段狭窄5例,长度2.0～3.0 cm;输尿管下段占位病变1例.结果 10例均行手术治疗.膀胱部分切除4例,其中同时切除双卵巢、子宫1例;输尿管部分切除输尿管膀胱吻合术3例,输尿管端端吻合术2例,肾输尿管全长切除1例.术后病理诊断均为子宫内膜异位症.术后9例服用17α-乙炔睾丸酮200 mg,2次/d,持续6～12个月.10例患者随访12～60个月,8例恢复良好;2例输尿管子宫内膜异位症患者术后18、24个月复发,予内置输尿管支架管,分别口服17α-乙炔睾丸酮及注射戈舍瑞林治疗3个月后症状缓解.结论 泌尿系子宫内膜异位症多无特异性表现,术前确诊困难,手术切除病灶效果好,辅助药物治疗可预防复发.     

泌尿系子宫内膜异位症临床诊治特点分析

目的 探讨泌尿系子宫内膜异位症的临床诊治特点.方法 女性泌尿系子宫内膜异位症患者10例.平均年龄39(28～49)岁.病史6个月～3年.膀胱子宫内膜异位症4例,临床表现为月经期尿路刺激症、下腹部坠痛不适感,其中伴肉眼血尿1例.B超、CT检查提示膀胱占位病变直径2.0～3.5 cm.输尿管子宫内膜异位症6例,左侧4例,右侧2例.临床表现为腰腹部不适4例,间断无痛性肉眼血尿1例,查体B超偶然发现肾积水1例.B超检查肾盂分离2.0～4.5 cm,输尿管中上段扩张1.0～2.0 cm,其中1例输尿管下端占位伴肾重度积水;CT检查输尿管下段狭窄5例,长度2.0～3.0 cm;输尿管下段占位病变1例.结果 10例均行手术治疗.膀胱部分切除4例,其中同时切除双卵巢、子宫1例;输尿管部分切除输尿管膀胱吻合术3例,输尿管端端吻合术2例,肾输尿管全长切除1例.术后病理诊断均为子宫内膜异位症.术后9例服用17α-乙炔睾丸酮200 mg,2次/d,持续6～12个月.10例患者随访12～60个月,8例恢复良好;2例输尿管子宫内膜异位症患者术后18、24个月复发,予内置输尿管支架管,分别口服17α-乙炔睾丸酮及注射戈舍瑞林治疗3个月后症状缓解.结论 泌尿系子宫内膜异位症多无特异性表现,术前确诊困难,手术切除病灶效果好,辅助药物治疗可预防复发.     

泌尿系子宫内膜异位症临床诊治特点分析

目的 探讨泌尿系子宫内膜异位症的临床诊治特点.方法 女性泌尿系子宫内膜异位症患者10例.平均年龄39(28～49)岁.病史6个月～3年.膀胱子宫内膜异位症4例,临床表现为月经期尿路刺激症、下腹部坠痛不适感,其中伴肉眼血尿1例.B超、CT检查提示膀胱占位病变直径2.0～3.5 cm.输尿管子宫内膜异位症6例,左侧4例,右侧2例.临床表现为腰腹部不适4例,间断无痛性肉眼血尿1例,查体B超偶然发现肾积水1例.B超检查肾盂分离2.0～4.5 cm,输尿管中上段扩张1.0～2.0 cm,其中1例输尿管下端占位伴肾重度积水;CT检查输尿管下段狭窄5例,长度2.0～3.0 cm;输尿管下段占位病变1例.结果 10例均行手术治疗.膀胱部分切除4例,其中同时切除双卵巢、子宫1例;输尿管部分切除输尿管膀胱吻合术3例,输尿管端端吻合术2例,肾输尿管全长切除1例.术后病理诊断均为子宫内膜异位症.术后9例服用17α-乙炔睾丸酮200 mg,2次/d,持续6～12个月.10例患者随访12～60个月,8例恢复良好;2例输尿管子宫内膜异位症患者术后18、24个月复发,予内置输尿管支架管,分别口服17α-乙炔睾丸酮及注射戈舍瑞林治疗3个月后症状缓解.结论 泌尿系子宫内膜异位症多无特异性表现,术前确诊困难,手术切除病灶效果好,辅助药物治疗可预防复发.     

Clinicopathological study of upper urinary tract tumors associated with bladder tumors

Among 535 cases of urothelial tumors (upper urinary tract and bladder tumors) from 1970 to 1988, 40 had upper urinary tract tumor associated with bladder tumor. Of 40 cases, 18 (45%) were synchronous, 17 (43%) were metachronous with primary upper urinary tract tumor followed by subsequent bladder tumor 18.5 +/- 14.1 (means +/- SD) months later and 5 (12%) were metachronous with primary bladder tumor followed by subsequent upper urinary tract tumor 40.2 +/- 13.6 months later. The incidence (17/52 = 0.32) of bladder tumor occurrence subsequent to primary upper urinary tract tumor was much higher than that (5/465 = 0.01) of upper urinary tract tumor subsequent to primary bladder tumor. The histologic grades of upper urinary tract tumor and associated bladder tumor were consistent in 73%. Except in 1 case, multiple occurrence of upper urinary tract tumor was always observed unilaterally on the side involved. The current results not only support the theory of multicentricity but raise the possibility that tumor cell implantation may play some role at least in the development of bladder tumor subsequent to upper urinary tract tumor.     

A clinical survey on malignant tumors of upper urinary tract in a 10-year period

A clinical survey was done on 107 patients with malignant tumor of the upper urinary tract (50 renal tumors, 25 renal pelvic tumors, 32 ureteral tumors) treated at our Department during the last 10 years (1976-1985). All types of tumors occurred more frequently in males than in females. The age groups of patients in which renal, renal pelvic and ureteral tumors were seen most frequently were those in their sixties, sixties and seventies, respectively. The most frequent primary symptom in patients with these three tumors was gross hematuria. The 5-year actual survival rate for the patients with renal, renal pelvic and ureteral tumors was 48.1, 37.9 and 31.8%, respectively. For all 3 kinds of tumors, the prognosis of patients with high-grade and high-stage cancer was worse than that of patients with low-grade and low-stage cancer. One-hour erythrocyte sedimentation rate for all the tumor types, weight of resected kidney in the case of renal tumor, and the class of urinary cytology and drip infusion pyelography findings in the case of renal pelvic and ureteral tumors were considered to be the factors possible influencing prognosis.     

输尿管硬镜下钬激光碎石取石术治疗输尿管上段结石112例

【摘要】〓目的〓探讨输尿管硬镜下钬激光碎石取石术治疗输尿管上段结石的临床效果及安全性。 方法〓应用输尿管硬镜下钬激光碎石取石术治疗112例输尿管上段结石患者。男63例,女49例,年龄18~87岁(46.7±13.6岁),左侧61例,右侧46例,双侧5例。结石长径0.7~2.2 cm(1.2±0.5 cm)。26例合并输尿管息肉,31例曾行体外冲击波碎石术,所有患侧肾脏均合并不同程度肾积水。 结果〓手术成功率88.4%(99/112),手术时间15~80 min(33.6±16.8 min),术后住院天数3~14天(4.7±2.1天)。所有患者均无严重肉眼血尿、输尿管穿孔、粘膜撕裂、输尿管镜石街形成等并发症。3例患者出现畏寒、高热,其中1例发展为尿源性脓毒血症,予以积极抗感染治疗后,症状逐渐缓解。结论〓输尿管硬镜下钬激光碎石取石术治疗输尿管上段结石是安全,有效的治疗方法。     

输尿管软镜钬激光碎石术治疗婴幼儿上尿路结石

目的探讨输尿管软镜联合钬激光治疗婴幼儿（<2岁）上尿路结石的可行性与有效性。 方法回顾性分析我科自2016年1月至2018年2月应用输尿管软镜治疗婴幼儿上尿路结石62例（77侧）。其中男37例,女25例,均为维吾尔族,年龄8～24个月,单侧上尿路结石47例,双侧上尿路结石15例。输尿管上段结石19侧,肾盂结石31侧,肾上盏结石18侧,下盏结石9侧,结石最大径8～25 mm。所有患儿均Ⅰ期置入双J管被动扩张输尿管2周,Ⅱ期采用导丝引导下直接置入输尿管软镜,配合200 μm钬激光光纤碎石,激光功率为20～30 W,术后留置双J管2～3周。 结果62例均入镜成功,51例行一次碎石手术（双侧上尿路结石6例）,9例双侧上尿路结石行两次碎石手术,2例下盏结石未能寻及继续观察。术后住院3～5 d,术后8周复查67侧结石排尽,结石清除率87.0%（67/77）,平均手术时间为35 min（20～55 min）。 结论输尿管软镜联合钬激光碎石治疗婴幼儿上尿路结石,有较高的清石率和临床安全性。     

一期微创经皮肾镜取石术（MPCNL）治疗双侧上尿路结石（附20例报告）

目的探讨一期微创经皮肾取石术（MPCNL）治疗双侧上尿路结石的疗效和安全性。方法总结一期微创经皮肾镜取石术治疗双侧上尿路结石20例的效果和并发症。结果双侧肾结石患者7例，结石清除率85％，平均手术时间160min；一侧输尿管上段结石对侧肾结石患者5例，结石清除率89％，平均手术时间142min：双侧输尿管上段结石患者8例，结石清除率92％，平均手术时间128min。手术出血量5-450ml，平均150ml。手术后25％（5／20）的患者出现超过38．0℃的发热，所有患者肾功能恢复正常，无严重术后并发症。结论对于身体情况良好，结石清除相对容易的双侧上尿路结石患者，一期MPCNL是安全可靠的，能减少患者总住院时间和费用。     

ESWL与输尿管镜碎石联合处理上尿路结石

目的：探讨对部分上尿路结石采用ESWI．与输尿管镜碎石联合处理的方法。方法：对70例上尿路结石患者采用ESWI。与输尿管镜下钬激光碎石（URS）联合交替治疗。其中输尿管结石48例,。肾结石22例。结果：结石总排净率为91．4％00（64／70）,其中输尿管结石排净率为95．8％（46／48）,肾结石排净率为81．8％（18／22）。3例治疗失败,其中1例输尿管结石因输尿管狭窄无法入镜;另2例肾结石,1例因交替治疗次数过多中途停止治疗,1例因结石硬度过大ESWI,不佳,均改为PCNL术。结论：ESW[。与URS联合交替进行的疗法处理上尿路结石,避免了创伤性治疗,扩大了ESWI,治疗范围,降低了URS手术难度,缩短了URS操作时间,提高了结石排净率,患者创伤微小、恢复快、并发症少,是治疗上尿路结石,特别是部分复杂性上尿路结石较理想的方法之一。     

A clinical study of tumor of the renal pelvis and ureter

We report 54 patients with urothelial tumors in upper urinary tract admitted to our hospital between July, 1962 and December, 1985. The patients consisted of 38 males and 16 females; side their ages ranged from 47 to 88 years with a mean of 63.4 years. The affected side was the right side in 21 cases, and the left side in 33 cases. Macro-or microhematuria was observed in 87% of the patients. Pathologically, 53 of the patients had transitional cell carcinoma and 1 had papilloma. Six patients had a past history of bladder tumor. Simultaneous bladder tumor was identified in 10 cases. Vesical recurrence was observed in 5 cases. Total nephroureterectomy with bladder cuff resection was employed as the surgical method in 21 cases, and total nephrectomy without bladder cuff resection in 11 patients. The actual five-year survival rate was 53% for all the patients; 52% for patients with renal pelvic tumors, 75% for those with ureteral tumors and 15% for those with renal pelvic and ureteral tumors. The patients who received nephroureterectomy had a postoperative survival rate similar to that of those who received nephroureterectomy with bladder cuff resection. A simultaneous bladder tumor lowered the survival rate.     

A clinical study of 33 cases of renal pelvic and ureteral tumors

Thirty-three cases of primary renal pelvic and/or ureteral tumors, i.e., 14 renal pelvic tumors, 14 ureteral tumors and 5 renal pelvic and ureteral tumors, treated at our hospital between November, 1976 and August, 1987 are reviewed retrospectively. Tumor occurred on the right side in 18 cases, left side in 14 cases and bilateral in one case. The patients ranged in age from 33 to 77 years (average 65.7 years), the sex ratio was 4.5:1 with male predominance over female. The most frequent symptoms were gross hematuria in 22 cases (67%). Interval from onset of initial symptoms to first visit within one month for 23 cases (70%). The major findings of excretory urograms were non-visualizing kidney in 18 cases (55%) and filling defect in 12 cases (36%). Positive urinary cytology was obtained in 18 cases (55%). Operative therapy was performed in all cases, namely, total nephroureterectomy with partial cystectomy in 21 cases (64%) and nephrectomy with transurethral ureterectomy in 7 cases (21%). Histopathologically, all cases but one case of squamous cell carcinoma were transitional cell carcinoma. Subsequent bladder tumors were found in 10 cases (30%). The overall survival rate at 1, 3 and 5 years were 84%, 68% and 61%, respectively by Kaplan-Meier method. In this series, grade and stage of tumor were the most influential factors for prognosis.     

急性肾后性肾功能不全的原因及综合处理（附6例报告）

目的：探讨急性肾后性肾功能不全的原因及临床处理。方法：回顾性分析2003～2008年6例肾后性肾功能不全患者的临床资料,总结治疗方法。结果：上尿路梗阻原因5例,其中盆腔肿瘤3例,子宫颈癌2例,子宫内膜癌1例;孤立肾、输尿管结石1例;乙状结肠癌根治术后造成双侧输尿管下段压迫1例。下尿路梗阻原因1例,为BPH并发尿潴留。急诊行输尿管逆行双J管置入术3例,其中双侧置管1例,单侧置管2例;血液透析后行ESWL1例;B超引导下肾穿刺造瘘术1例;留置尿管肾功能恢复后行TURP术1例。6例患者梗阻解除后,3～10天肾功能有不同程度恢复。结论：导致急性肾后性肾功能不全的原因众多,以肿瘤、结石、前列腺增生进行性尿潴留为主。急诊处理原则为解除梗阻,改善肾功能。待患者肾功能恢复后,针对不同病因进行治疗。     

截石位微创经皮肾镜联合逆行输尿管镜治疗上尿路疾病

目的探讨截石位微创经皮肾镜联合逆行输尿管镜在处理上尿路疾病中的临床应用价值。方法本组23例中，男15例，女8例。年龄21．69岁，平均（45＋13）岁。23例行腹部平片（KUB）＋静脉肾盂造影（IVU）、超声检查或CT检查：20例为肾结石或合并输尿管结石（其中对侧2例），2例为输尿管多发性结石，1例为腹腔镜膀胱癌根治术＋原位回肠膀胱术后双侧输尿管下端狭窄。肾结石最大径为1．2～3．4cm，输尿管结石长径0．8—1．7cm.23例均伴有肾积水，其中轻度积水7例，中度积水14例，重度积水2例。采用截石位并于患侧腰肋部用水袋垫高，同时进行逆行置管或输尿管镜及PCNL手术。结果本组23例手术均成功，无1例出现结肠损伤等严重并发症。20例。肾结石患者中一期取净结石17例，结石取净率达85％。所有输尿管结石均一期处理干净。输尿管下端狭窄者采用顺行与逆行相结合扩张成功并留置8F双J管。结论截石位行微创经皮肾镜术联合逆行输尿管镜术方便术者顺行及逆行操作，术中无需变换体位，利于击碎的结石冲出，患者及术者体位舒适，避免呼吸及循环严重并发症，是处理上尿路结石安全、高效、方便的新方法。     

Evaluation of urinary cytology for upper urinary tract disease

One hundred and seventy-two patients with upper urinary tract disease were examined by cytological study of ureteral urine which was taken by ureteral catheterization. Of 139 patients with benign disease or ureteral stricture due to non-urological cancer, only one case with renal cyst revealed positive findings (false positive rate: 0.7%). Two positive cases, which were a renal hemorrhage without followup and a uterine cervical cancer with squamous cancer cells in the ureteral urine, were excluded. Although 6 of 17 (35%) uroepithelial cancers in the upper urinary tract were registered as positive, this examination was little use for detecting stage pTa, grade 1 or papillary non-invasive tumors. However, 2 out of 12 (17%) renal pelvic or ureteral cancer patients with negative results of voided urine were cytologically detected by ureteral urine. Five out of 6 cases of these cancers demonstrated malignant cells in the renal pelvic urine sampled from surgical specimen. We have recently experienced aspiration cytology for upper urinary tract disease, using the percutaneous puncture method, and five of 7 upper urinary tract patients were cytologically diagnosed. This procedure could be valuable for detecting even patients with associated bladder cancer or failure of ureteral catheterization.     

输尿管软镜钬激光碎石治疗重复输尿管畸形合并上尿路结石5例报告

目的探讨输尿管软镜钬激光碎石治疗重复输尿管畸形合并上尿路结石的有效性和安全性。方法回顾2012年7月至2014年5月我院收治的5例采用输尿管软镜钬激光治疗的重复输尿管畸形合并上尿路结石患者的临床及随访资料,结合文献资料进行分析。男性2例,女性3例;平均年龄32.2(25~40)岁;上位肾结石1例,下位肾结石1例,输尿管上段结石2例,输尿管上段结石合并下位肾结石1例。结石大小平均1.5(1.0~2.2)cm。结果 4例患者成功碎石,1例因输尿管狭窄上鞘失败改为经皮肾镜碎石术。术后1个月结石完全排净率为75%(3/4),1例残留结石经体外冲击波碎石后结石排出。所有患者术中及术后无输尿管损伤,无明显出血、发热及尿脓毒血症发生。随访3~20个月,结石无复发,患者的肾积水均有不同程度的改善。结论输尿管软镜钬激光碎石治疗重复输尿管畸形合并上尿路结石安全、有效。     

内镜下钬激光治疗早期上尿路上皮肿瘤特殊病例1O例报告

目的探讨内镜下钬激光治疗特殊早期上尿路上皮肿瘤的安全性及有效性。方法2002年4月～2010年5月,对10例不适合行根治性。肾输尿管切除术的早期上尿路上皮肿瘤患者行内镜下钬激光治疗,其中输尿管肿瘤7例（1例合并膀胱肿瘤）,肾盂肿瘤3例。单发7例,多发3例。术前肿瘤分期cTa～cT1。3例对侧已行肾输尿管全长切除,2例孤立肾,3例肾功能不全,1例2～3级心功能不全,1例肿瘤小（〈1cm,位于。肾盂,单发且表浅）。输尿管硬镜治疗7例,软镜1例,微通道经皮肾镜2例。术后行丝裂霉素上尿路及膀胱灌注化疗。结果10例术后随访2年,无肿瘤死亡。1例术后6个月输尿管狭窄,其余均未出现大出血、严重感染、周围脏器损伤及全身肿瘤转移。复发4例,其中1例输尿管合并膀胱肿瘤者膀胱内复发,1例为肾盂内单发肿瘤复发,2例为输尿管单发肿瘤复发。该4例随访5年,1例未见肿瘤复发与转移,3例复发3—4次,且为尿路多处复发,行肾盂输尿管癌根治术,其中2例术后血液透析1年内肿瘤转移死亡。结论对不适合行根治性肾输尿管切除术的早期上尿路上皮肿瘤,内镜下钬激光治疗短期内是安全有效的。     

经皮肾微造瘘吸引碎石清石鞘在微创经皮肾镜取石术中的应用

目的：探讨应用专利设计的经皮肾微造瘘吸引碎石清石鞘（简称专利鞘）治疗上尿路结石的临床疗效和安全性.方法：回顾性分析2008年8月～2009年10月应用专利鞘行微创经皮肾镜取石术（MPCNI.）治疗上尿路结石患者198例的临床资料,其中肾结石138例,输尿管上段结石46例,单侧肾结石并同侧或对侧输尿管结石12例,双肾结石并双侧输尿管上段结石2例.均应用专利鞘进行MPCNL,并对手术时间、肾盂内压、清石率、手术并发症等进行分析.结果：198例均一期建立通道.采用单通道取石192例,双通道取石5例,三通道取石1例.平均手术时间（46±10.8）min,术中监测肾盂内压力平均（0.28±0.068）kPa（1 mmHg=0.133 kPa）;术后血红蛋白含量较术前平均下降（4.2±1.5）%,术中输血5例,术后2例出血严重者经高选择性肾动脉栓塞治愈.一期清石率为95.95%.术后3天出现体温≥38.5℃者3例.结论：应用专利鞘行MPCNL治疗上尿路结石安全、高效,临床效果显著.